Novel low-avidity glypican-3 specific CARTs resist exhaustion and mediate durable antitumor effects against HCC.
Hepatology
; 76(2): 330-344, 2022 08.
Article
in En
| MEDLINE
| ID: mdl-34897774
Full text:
1
Database:
MEDLINE
Main subject:
Carcinoma, Hepatocellular
/
Liver Neoplasms
Limits:
Animals
/
Humans
Language:
En
Journal:
Hepatology
Year:
2022
Type:
Article
Affiliation country:
United States